Goldman Sachs Adjusts Illumina EPS, Revenue Estimates | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Investment bank Goldman Sachs today revised revenue and earnings per share estimates for Illumina for the next three years to "reflect our updated view on quarterly revenue pacing, recent financing activities, and corresponding share repurchase."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.